GLAXOSMITHKLINE PHARMA LT Fair Value
GLAXO · Healthcare · Current price ₹2,999.7
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹500 | 46% ROE fading to 12% over ~20 yrs, on ₹134 book |
| Relative P/E | ₹2,392 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹429 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹3,081 | Street consensus 12-month target price |
Is GLAXOSMITHKLINE PHARMA LT undervalued?
DocStoX estimates the fair value of GLAXOSMITHKLINE PHARMA LT at ₹1,391 per share, versus the current market price of ₹3,000. That puts the stock about -53.6% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹500), Relative P/E (₹2,392), Graham floor (₹429), Analyst target (₹3,081). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹429 (bear) to ₹1,391 (base) to ₹3,081 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on GLAXOSMITHKLINE PHARMA LT
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.